Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

  1. Thomas F. Rogers
  2. Fangzhu Zhao
  3. Deli Huang
  4. Nathan Beutler
  5. Alison Burns
  6. Wan-ting He
  7. Oliver Limbo
  8. Chloe Smith
  9. Ge Song
  10. Jordan Woehl
  11. Linlin Yang
  12. Robert K. Abbott
  13. Sean Callaghan
  14. Elijah Garcia
  15. Jonathan Hurtado
  16. Mara Parren
  17. Linghang Peng
  18. James Ricketts
  19. Michael J. Ricciardi
  20. Stephen A. Rawlings
  21. Davey M. Smith
  22. David Nemazee
  23. John R. Teijaro
  24. James E. Voss
  25. Raiees Andrabi
  26. Bryan Briney
  27. Elise Landais
  28. Devin Sok
  29. Joseph G. Jardine
  30. Dennis R. Burton
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The development of countermeasures to prevent and treat COVID-19 is a global health priority. In under 7 weeks, we enrolled a cohort of SARS-CoV-2-recovered participants, developed neutralization assays to interrogate serum and monoclonal antibody responses, adapted our high throughput antibody isolation, production and characterization pipeline to rapidly screen over 1000 antigen-specific antibodies, and established an animal model to test protection. We report multiple highly potent neutralizing antibodies (nAbs) and show that passive transfer of a nAb provides protection against high-dose SARS-CoV-2 challenge in Syrian hamsters. The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19. The nAbs define protective epitopes to guide vaccine design.

Related articles

Related articles are currently not available for this article.